The role of biological response modifiers in the management of patients with colorectal cancer
- 31 August 1995
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (7) , 1323-1325
- https://doi.org/10.1016/0959-8049(95)00211-z
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.The Journal of Experimental Medicine, 1994
- Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.The Journal of Experimental Medicine, 1994
- Costimulation of T cells for tumor immunityImmunology Today, 1993
- Molecular Mechanisms Used by Tumors to Escape Immune RecognitionJournal of Immunotherapy, 1993
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Effects of Immunomodulatory Cytokines on the Presentation of Tumor-Associated Antigens by Epidermal Langerhans CellsJournal of Investigative Dermatology, 1992
- Fluorouracil and recombinant interferon alfa‐2a in advanced gastrointestinal neoplasmsBritish Journal of Haematology, 1991
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990